At Work With WebMD's Leming on audience development and lessons from CNN.com

WebMD's Leming on audience development and lessons from CNN.com

The vice president of audience development talks about her days in the dot-com world and how struggling in a new role shaped her career.

Careers What do employers want? We ask three execs for their secrets and their insights

What do employers want? We ask three execs for their secrets and their insights

They share their insights, secrets, worries, and everything else in between.

Careers The industry's winning — and losing — job titles, based on salary

The industry's winning — and losing — job titles, based on salary

Hint: it pays to be an EVP.

Sponsored Sudler New York's John Marchese on the New Talent Pool

Sudler New York's John Marchese on the New Talent Pool

"It's easy to 'fill open positions,'" Marchese says. "We've banned that phrase. If you do that, you're just checking boxes on a list."

Careers Pharma marketing salaries veer off track, dropping 2.6% in 2016

Pharma marketing salaries veer off track, dropping 2.6% in 2016

Execs say that career prospects are better than ever. Yet data from MM&M's annual Career and Salary Survey reveals a decline in growth.

Sponsored Data, Technology, and Medicine: How They Intersect

Data, Technology, and Medicine: How They Intersect

The intersection of data, technology, and medicine is rapidly changing how doctors practice, drug companies market, and patients engage with the healthcare system.

Commercial Infographic: How physicians share online info with patients and other docs

Infographic: How physicians share online info with patients and other docs

The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.

Commercial Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.

Commercial The co-pay card debate simmers, as payers push back

The co-pay card debate simmers, as payers push back

Will this payer pressure pose an existential threat to co-pay cards even though patients love them?

Commercial Drugmakers revive R&D focus on long stagnant women's health market

Drugmakers revive R&D focus on long stagnant women's health market

Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?

Commercial Top 25 women's health products, ranked by 2016 forecasts

Top 25 women's health products, ranked by 2016 forecasts

Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.

Pipeline Long neglected, the osteoporosis market prepares for new entrants

Long neglected, the osteoporosis market prepares for new entrants

The osteoporosis drug market is bracing for the advent of potentially game-changing treatments.

Commercial Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Only one new osteoporosis drug has been approved over the last six years.

Features Read the complete August 2016 digital edition

Read the complete August 2016 digital edition

Read about MM&M's inaugural Hall of Femme event and the rest of the MM&M August issue.

Payers/Managed Markets PBMs push forward toward outcomes-based pricing, despite challenges

PBMs push forward toward outcomes-based pricing, despite challenges

The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.

Features Read the complete July 2016 digital edition

Read the complete July 2016 digital edition

Read the 2016 Agency Issue in its entirety.

Sponsored Patient-Centricity: There's Always Room for Improvement

Patient-Centricity: There's Always Room for Improvement

It's unlikely that pharma will ever achieve the degree of consumer love directed at Amazon and Apple but the shift taking place will open up doors for pharma organizations.

Careers Christine Coyne on the moment with a male boss that influenced her career

Christine Coyne on the moment with a male boss that influenced her career

A story about a boss giving away a woman's bonus to a man based on his breadwinning status resonated with Hall of Femme attendees.

Sponsored The Story Behind the Story, Live From Cannes, Presented by McCann Health

The Story Behind the Story, Live From Cannes, Presented by McCann Health

McCann Health, the 2016 Lions Health Network of the Year, and Campaign invited top marketers and visionary artists to discuss creativity during this year's Lions Health festival.

Technology 8 ways for pharma to improve the way it uses Twitter

8 ways for pharma to improve the way it uses Twitter

Twitter's health team offers advice on how pharma and healthcare companies can more effectively utilize 140 characters.

Commercial Infographic: Type 2 diabetes, a country-by-country snapshot

Infographic: Type 2 diabetes, a country-by-country snapshot

Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.

Technology Healthcare marketers: Don't forget about the baby boomers

Healthcare marketers: Don't forget about the baby boomers

Baby boomers have taken to health tech with surprising ease, opening up a wealth of opportunities for marketers savvy enough to pursue them.

Pipeline CAR-T therapies: the future of cancer care, or an industry pipe dream?

CAR-T therapies: the future of cancer care, or an industry pipe dream?

While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.

Pipeline Top 25 oncology products in 2015

Top 25 oncology products in 2015

Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.

Commercial As immuno-oncology therapies evolve, so will the marketing

As immuno-oncology therapies evolve, so will the marketing

Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.

Corporate Avanir marketing chief on selling first-in-class therapies

Avanir marketing chief on selling first-in-class therapies

Avanir's success with Nuedexta sparked the attention of several suitors. In 2014 the company reached a deal to be sold to Otsuka Pharmaceutical for around $3.5 billion

Features Read the complete June 2016 digital edition

Read the complete June 2016 digital edition

Read the 2016 June issue in its entirety.

Features 100 quotes: What they reveal about the state of healthcare advertising

100 quotes: What they reveal about the state of healthcare advertising

Visions, challenges, and advice: Here are 100 quotes from 100 agency leaders, compiled from the MM&M Agency Issue.

Agencies 3 questions for 5 of the agency world's leading executives

3 questions for 5 of the agency world's leading executives

Five executives from the industry's largest holding companies discuss their move away from the traditional network structure.

Agencies How the healthcare agency solar system evolved this year

How the healthcare agency solar system evolved this year

A number of mergers and acquisitions among healthcare agencies in 2015 and 2016 changed the landscape.

Agencies Revenues surge as agencies adapt to health-tech, payer trends

Revenues surge as agencies adapt to health-tech, payer trends

Healthcare agencies focus on freeing pharma brands from their collaboration cocoons to work with health tech companies, while squaring away access concerns.

Agencies At Work With: Kantar Health's Tom Haskell

At Work With: Kantar Health's Tom Haskell

The co-founder of Mapquest.com talks about his move from online mapping to healthcare, and what he likes most meeting with clients.

Upward Moves Digitas Health LifeBrands' Susan Manber on telling a healthy story

Digitas Health LifeBrands' Susan Manber on telling a healthy story

The chief planning officer of North America talks about strategy and how to tell an engaging health story.

Data/Analytics The CIO, reimagined for pharma

The CIO, reimagined for pharma

Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.

Technology Pharma companies turn to wearables to improve R&D

Pharma companies turn to wearables to improve R&D

Drugmakers and tech companies are developing wearables and using popular fitness trackers like the Fitbit in clinical trials to gain insights about Parkinson's Disease.

Features Leadership Exchange: Engaging the Millennial Doctor

Leadership Exchange: Engaging the Millennial Doctor

In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.

Sponsored The Patient Journey 2016: PDR

The Patient Journey 2016: PDR

Features Why Healthcare Needs "Mad Women"

Why Healthcare Needs "Mad Women"

Besides being the right thing to do, elevating woman leaders confers a competitive edge to companies, a fact confirmed by multiple studies.

Features Telehealth: Improving the customer experience but still an unknown for pharma

Telehealth: Improving the customer experience but still an unknown for pharma

Although telehealth is still in its early stages, it's building momentum — with good reason.

Commercial Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.

Commercial What do physicians think about biosimilars?

What do physicians think about biosimilars?

A SERMO poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"

Commercial Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

Features Why are We Still Shortchanging Women in the Workplace?

Why are We Still Shortchanging Women in the Workplace?

Why would any CEO tolerate a corporate culture that holds people back?

Commercial 4 trends with the potential to change behavior in the patient journey

4 trends with the potential to change behavior in the patient journey

It's a common refrain in healthcare and among patients, providers, and payers: Despite massive investment, no one has figured out how to change human behavior.

Therapeutic Focus Top 25 infectious disease products in 2015

Top 25 infectious disease products in 2015

To no surprise, Gilead Sciences' Harvoni and Sovaldi were the top-selling infectious disease products in 2015.

Therapeutic Focus Drugmakers renew interest in antibiotic development

Drugmakers renew interest in antibiotic development

The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.

Therapeutic Focus Competition may threaten Gilead as market leader

Competition may threaten Gilead as market leader

Even as Gilead prepares to launch a third hepatitis-C product, drugs offering better antimicrobial resistance are angling for their own moments in the spotlight.

Therapeutic Focus Top 20 autoimmune products, 2015

Top 20 autoimmune products, 2015

AbbVie's Humira is the top selling autoimmune drug in 2015, bringing in $10.6 billion in sales in the U.S. alone.

Therapeutic Focus With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy

With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy

The bar for market success has been set high for baricitinib.

Therapeutic Focus Fueled by precision medicine, drugmakers delve deeper in autoimmune diseases

Fueled by precision medicine, drugmakers delve deeper in autoimmune diseases

Drugmakers are working toward developing drugs in lupus, celiac disease, and other conditions that have rarely captured their attention in the past.

Agencies 2016 Pharma Report: All the data in one place

2016 Pharma Report: All the data in one place

Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.

Features

2016 Pharma Report: Index of top 20 drugmakers

The index of the top 20 drugmakers from the 2016 pharma report.

Corporate

20. Bristol-Myers Squibb

Immuno-oncology was the story at Bristol-Myers Squibb in 2015.

Corporate

19. Valeant

So, heard anything lately about Valeant? Yeah. Even by the standards of an industry under siege, Valeant experienced quite the tumultuous last year or so.

Corporate

18. Biogen

Biogen's 2015 was hindered by less-than-stellar sales of its flagship multiple sclerosis treatment Tecfidera.

Corporate

17. Mylan

After turning its back on an offer from generics competitor Teva, Mylan stepped up with an unsuccessful hostile takeover bid for generic drugmaker Perrigo.

Corporate

16. Boehringer Ingelheim

In an effort to overcome pricing pressures and bounce back from patent losses, Germany's second-largest drugmaker has unloaded assets and reshuffled its management team.

Corporate

15. GlaxoSmithKline

The year 2015 was one of restructuring for GlaxoSmithKline.

Corporate

14. Novo Nordisk

Novo Nordisk wants to own the obesity space much in the same way that it has attempted to dominate diabetes.

Corporate

13. Eli Lilly

Diabetes drugs headlined Eli Lilly's 2015 results, with Humalog and Trulicity contributing mightily to the upward sales curve.

Corporate

12. AbbVie

Coming off what AbbVie's board dubbed an "exceptional year," 2016 may sting.

Corporate

11. Allergan

Allergan and Pfizer agreed to scrap their pending mega-merger following an early April power play by the U.S. government.

Agencies

10. Sanofi

The big news: Sanofi and its partner Regeneron received approval for the first PCSK9 inhibitor to come to market in the U.S.: Praluent. But Praluent's sales to date haven't awed analysts.

Corporate

9. Roche

On the sales and profit forecast front, analysts say that Roche missed the mark in 2015.

Corporate

8. Amgen

As Amgen executives continue to toast a spectacular 2015 performance — double-digit growth from five of eight blockbusters — CEO Robert Bradway has cast a keen eye on the biotech pioneer's future.

Corporate

7. Teva

Analysts agree that Teva is casting a healthy financial shadow.

Corporate Spending on drugs is up, but by how much?

Spending on drugs is up, but by how much?

Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.

Agencies Post Pfizer, Allergan faces the future

Post Pfizer, Allergan faces the future

Mere days after the Pfizer deal collapsed, top Allergan executives had nary an air of regret about them.

Corporate

6. AstraZeneca

AstraZeneca has embarked on what's likely to be a long, rough ride.

Corporate

5. Pfizer

Pfizer's dream to shave the top off a rising U.S. tax bill — and level the playing field with overseas competitors — was dashed.

Corporate

4. Novartis

There are two primary reasons Novartis anticipates flat sales during 2016: Its hallmark cancer drug Gleevec recently came off patent and its Alcon ophthalmic business has seen declining growth rates.

Corporate

3. Merck

Merck's landmark approval in 2015 was for immunotherapy Keytruda, which was cleared in October as a second-line treatment for the most common form of skin cancer.

Features

2. Johnson & Johnson

J&J has earmarked a pile of cash — in the neighborhood of $18.5 billion — for future acquisition targets, but is patiently pacing the sidelines for the best players to walk onto the field.

Corporate

1. Gilead Sciences

Gilead's current and future success lies in the hands of its antiviral franchise.

MMM Hall of Femme MM&M's Hall of Femme: 20 women to watch

MM&M's Hall of Femme: 20 women to watch

The MM&M Women to Watch, part of our inaugural Hall of Femme, salutes 20 aspiring healthcare commercial and marketing execs distinguishing themselves.

MMM Hall of Femme MM&M's Hall of Femme: 16 women leaders who changed the industry

MM&M's Hall of Femme: 16 women leaders who changed the industry

The 16 women profiled here number among those who have bridged the gender gap in agencies, biopharma, and medtech.

Pipeline Infographic: the growing biosimilar market in the U.S.

Infographic: the growing biosimilar market in the U.S.

The FDA has approved two biosimilars, but questions remain about how quickly providers and patients in the U.S. will adopt them.

Corporate Be a better mentor, says Baxalta's Leonardi

Be a better mentor, says Baxalta's Leonardi

Too often left undiscussed is that a powerful business case can be made for more frequent and focused mentorship.

Agencies Intouch Solutions' Weissberg on the rising payer voice

Intouch Solutions' Weissberg on the rising payer voice

The group director of Intouch Solutions' newly launched market access business is betting that the payer will gain in influence.

Campaigns Using humor: Why pharma doesn't need to fear social media

Using humor: Why pharma doesn't need to fear social media

Healthcare and tech executives say it's possible for pharma to engage, use humor, and have fun on social media.

Features Guidemark Health's Fascetti on Ads that Change Behavior

Guidemark Health's Fascetti on Ads that Change Behavior

Curious what a 2016 Lions Health judge thinks about creativity? Here's what defines behavior-changing creativity for Guidemark Health's Tina Fascetti.

Agencies At Work With: Cello Health's Jon Bircher

At Work With: Cello Health's Jon Bircher

"I continue to look for ways to stretch myself or ways I can get involved or influence the business," said the new CCO of Cello Health.

Features Which brands spent the most on professional ads in 2015?

Which brands spent the most on professional ads in 2015?

Here are the brands and companies that advertised the most on professional ads in 2015.

Features When it comes to professional ads, print makes its comeback

When it comes to professional ads, print makes its comeback

Following print's best year since 2011, it's time to rewrite those journal-advertising obituaries. Medical-surgical print journal spending in 2015 was up 8.4% to $372 million.

Sponsored Game Changers 2016: MicroMass

Game Changers 2016: MicroMass

Sponsored Game Changers 2016: 4INFO

Game Changers 2016: 4INFO

Sponsored Game Changers 2016: Skipta

Game Changers 2016: Skipta

Sponsored Game Changers 2016: PDR

Game Changers 2016: PDR

Sponsored Game Changers 2016: XL Alliance

Game Changers 2016: XL Alliance

OPINION

Email Newsletters